Adaptive Biotechnologies Highlights clonoSEQ Data Guiding Blood Cancer Treatment at ASH 2025

Reuters12-06 21:30

<a href="https://laohu8.com/S/ADPT">Adaptive Biotechnologies</a> Highlights clonoSEQ Data Guiding Blood <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a> at ASH 2025

Adaptive Biotechnologies Corporation has announced new data highlighting the growing use of its clonoSEQ® test for measurable residual disease (MRD) monitoring in hematology-oncology, showcased in 90 abstracts at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition, held December 6-9, 2025. Among these, 17 abstracts demonstrate how next-generation sequencing-based MRD status is being used to guide clinical treatment decisions in blood cancer care. Notably, results from the phase II EndRAD study were presented, supporting the use of NGS MRD status before allogeneic hematopoietic cell transplantation (HCT) to guide non-total body irradiation conditioning approaches in children and young adults with B-cell acute lymphoblastic leukemia, with data showing comparable survival outcomes to standard TBI regimens.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598021-en) on December 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589475825?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-06 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589475825","market":"us","top_or_hot":-1,"title":"Adaptive Biotechnologies Highlights clonoSEQ Data Guiding Blood Cancer Treatment at ASH 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> Highlights clonoSEQ Data Guiding Blood <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a> at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adaptive Biotechnologies Corporation has announced new data highlighting the growing use of its clonoSEQ® test for measurable residual disease (MRD) monitoring in hematology-oncology, showcased in 90 abstracts at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition, held December 6-9, 2025. Among these, 17 abstracts demonstrate how next-generation sequencing-based MRD status is being used to guide clinical treatment decisions in blood cancer care. Notably, results from the phase II EndRAD study were presented, supporting the use of NGS MRD status before allogeneic hematopoietic cell transplantation (HCT) to guide non-total body irradiation conditioning approaches in children and young adults with B-cell acute lymphoblastic leukemia, with data showing comparable survival outcomes to standard TBI regimens.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598021-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies Highlights clonoSEQ Data Guiding Blood Cancer Treatment at ASH 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies Highlights clonoSEQ Data Guiding Blood Cancer Treatment at ASH 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-06 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> Highlights clonoSEQ Data Guiding Blood <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a> at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adaptive Biotechnologies Corporation has announced new data highlighting the growing use of its clonoSEQ® test for measurable residual disease (MRD) monitoring in hematology-oncology, showcased in 90 abstracts at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition, held December 6-9, 2025. Among these, 17 abstracts demonstrate how next-generation sequencing-based MRD status is being used to guide clinical treatment decisions in blood cancer care. Notably, results from the phase II EndRAD study were presented, supporting the use of NGS MRD status before allogeneic hematopoietic cell transplantation (HCT) to guide non-total body irradiation conditioning approaches in children and young adults with B-cell acute lymphoblastic leukemia, with data showing comparable survival outcomes to standard TBI regimens.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598021-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL1rnQPM:1","article_id":"2589475825","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589475825","pubTimestamp":1765027819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Adaptive Biotechnologies Corporation has announced new data highlighting the growing use of its clonoSEQ test for measurable residual disease  monitoring in hematology-oncology, showcased in 90 abstracts at the 67th American Society of Hematology  Annual Meeting and Exposition, held December 6-9, 2025. Among these, 17 abstracts demonstrate how next-generation sequencing-based MRD status is being used to guide clinical treatment decisions in blood cancer care. Notably, results from the phase II EndRAD study were presented, supporting the use of NGS MRD status before allogeneic hematopoietic cell transplantation  to guide non-total body irradiation conditioning approaches in children and young adults with B-cell acute lymphoblastic leukemia, with data showing comparable survival outcomes to standard TBI regimens.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-g","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","ADPT":"Adaptive Biotechnologies Corp","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","BK4121":"生命科学工具和服务","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Adaptive Biotechnologies在ASH 2025上强调clonoSEQ数据指导血癌治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":0.9,"NDAQ":0.9},"content_text":"Adaptive Biotechnologies Highlights clonoSEQ Data Guiding Blood Cancer Treatment at ASH 2025\n    \n\n        Adaptive Biotechnologies Corporation has announced new data highlighting the growing use of its clonoSEQ® test for measurable residual disease (MRD) monitoring in hematology-oncology, showcased in 90 abstracts at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition, held December 6-9, 2025. Among these, 17 abstracts demonstrate how next-generation sequencing-based MRD status is being used to guide clinical treatment decisions in blood cancer care. Notably, results from the phase II EndRAD study were presented, supporting the use of NGS MRD status before allogeneic hematopoietic cell transplantation (HCT) to guide non-total body irradiation conditioning approaches in children and young adults with B-cell acute lymphoblastic leukemia, with data showing comparable survival outcomes to standard TBI regimens.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598021-en) on December 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589475825","isCrawlerRequest":true}